|
4D Pharma PLC - Leeds, England-based pharmaceutical company - Releases its publication of pre-clinical research on mice regarding live biotherapeutic MRx0006 for the treatment of autism spectrum disorder. Says research shows LBP MRx0006 can attenuate core behavioural deficits in a mouse model of autism, improving social deficits, repetitive and anxiety-like behaviours. ‘Mechanistically, MRx0006 increased in the brains of ASD mice the expression of neuropeptide hormones known to regulate social and anxiety behaviour,’ 4D Pharma adds.
Research Director Imke Mulder says: ‘With this research we are moving the field beyond associations to demonstrate the meaningful impacts that can be achieved by a single strain of bacteria, and identifying mechanisms through which the gut microbiome influences the central nervous system and behaviour.’
4D pharma says its live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. Live biotherapeutics is an emerging class of drugs, defined by the Food & Drug Administration as biological products that contain a live organism.
Current stock price: 16.30 pence
12-month change: down from 8,410p
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
